Breast Cancer Stage Clinical Trial
Official title:
Clinical Evaluation of Opto-Acoustic Image Quality With the Gen 2 Imagio System
Verified date | March 2023 |
Source | Seno Medical Instruments Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study performs the first clinical evaluation of the Gen 2 Imagio System in a clinical setting to assess image quality with both the IUS ultrasound only probe and the OA/US (duplex probe).
Status | Completed |
Enrollment | 38 |
Est. completion date | February 17, 2022 |
Est. primary completion date | February 17, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Has a signed and dated informed consent, prior to initiation of any study-related activities. 2. Is at least 18 years of age. 3. Have been referred for a breast US because of a breast lesion/mass finding via a palpable lump or per standard of care imaging. 4. Is willing and able to comply with protocol-required scans Exclusion Criteria: 1. Is pregnant or lactating. 2. Has a condition or breast impediment (i.e. insect bites, poison ivy, rash, open wounds, chafing of the skin, scar, tattoos, moles, hematoma, nipple rings, etc.) which could interfere with the intended field of view. 3. Is experiencing photo-toxicity associated with currently taking, or having taken, photosensitizing agents within the previous 72 hours such as some sulfur containing drugs, ampicillin, tetracycline. 4. Is currently undergoing phototherapy. 5. Has a history of any photosensitive disease (e.g., porphyria, lupus erythematosus) or undergoing treatment for a photosensitive disease and is experiencing photosensitivity. 6. Has had an adverse reaction in the past to medical laser procedures, such as laser hair removal or laser tattoo removal. 7. Has had prior benign excisional breast biopsy on breast of interest within the past 18 months. 8. Currently has mastitis. 9. Prisoners |
Country | Name | City | State |
---|---|---|---|
United States | UT Health | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Seno Medical Instruments Inc. | American College of Radiology |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Imagio Image Sets Collected | Obtain ultrasound only probe images and OA/US (both gray scale and OA) probe images as measured by the receipt of image sets for each subject enrolled. | Baseline | |
Primary | Number of Subjects With Completed Pathology Results | Provide breast pathology results per subject (except BI-RADS 1, 2 and 3 (as applicable)) if subject's study mass is biopsied | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04741204 -
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer
|
Phase 4 | |
Not yet recruiting |
NCT03959397 -
Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer
|
Phase 2 | |
Completed |
NCT04929964 -
COVID-19 Pandemic: Effect on Management of Patients With Breast Cancer
|
||
Completed |
NCT05463276 -
The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study
|
||
Active, not recruiting |
NCT06234488 -
Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study
|
||
Completed |
NCT03530696 -
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05190770 -
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05142800 -
Screening For BCRL In Targeted Therapy For Breast Cancer
|